News

A recent publication argues that advocacy efforts from patient advocates, health care professionals, and professional societies are necessary at the state level to increase access to biomarker testing.

Among patients with CLL with disease progression who were treated with ibrutinib, overall survival was significantly longer when next-line treatment was chimeric antigen receptor T-cell therapy or venetoclax-based treatment compared to other...

Findings from a recently study revealed opportunities for enhancing rates of DNA mismatch repair/microsatellite instability testing and reporting, possibly by way of integration into quality control and accreditation metrics.

Significant variations exist in somatic biomarker testing across subgroups of patients with metastatic colorectal cancer and identification of genomic alterations can aid in ascertaining targeted treatment and in enhancing clinical outcomes.

Jaktinib reduces spleen volume and improves anemia and other clinical symptoms with acceptable tolerability in JAK inhibitor-naïve patients with myelofibrosis, according to results from a phase 2 trial.

Findings from a recent study suggest disparities in next-generation sequencing-based testing rates between Black and White patients with non-small cell lung cancer or metastatic colorectal cancer.

Registration trials focused on oncology are expanding in number and are continually enrolling patients from many different countries and regions; according to findings from a recently published study, regional outcome variations occur in more...

Outcomes in relapsed/refractory myeloma remain poor, and novel therapy approaches are necessary, according to findings from a study published in Clinical Lymphoma, Myeloma & Leukemia.

Results from a recent study indicated that mantle cell lymphoma patients have higher relative risks of respiratory, blood, and infectious disease compared to healthy comparators and that late effects varied very little by treatment with or...

Mantle cell lymphoma with optic nerve involvement is a rare oncologic process, with whole-brain radiation therapy conventionally utilized as a palliative treatment.